OTC switch marketing exclusivity may be facilitated by "paper trail," attorney tells FDLI.
This article was originally published in The Tan Sheet
Executive Summary
OTC SWITCH MARKETING EXCLUSIVITY AWARDS MAY BE FACILITATED by companies developing a "detailed record" of discussions with FDA regarding clinical trials undertaken toward approval, Washington, D.C. attorney Peter Safir (Kleinfeld, Kaplan, and Becker) suggested at the Food and Drug Law Institute's "Pharmaceutical Update" meeting on May 14.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
People In Brief
Perrigo promotes in pricing, planning
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: